[Cross-over study of benfluorex and a hypolipemic agent in diet-resistant types IV and II b hyperlipemia (author's transl)].
The effects of benfluorex and a hypolipemic agent were compared in 24 patients with types IV or II b hyperlipoproteinemia unimproved after 4 months diet, by means of a cross-over study with two periods of two months treatment separated by two months without treatment. Results showed similar efficacy for each treatment against lipid parameters; statistically significant variations in body weight (-0,8%; p < 0,0001), fasting blood sugar (-11,7%; p < 0.001), and of uric acid (-8,3%; P greater than or equal to 0,001) with benfluorex VS., respectively (-0,1%; P: NS), (+ 3,4%; P < 0.05), and (+ 1,3% PP: NS) with the hypolipemic agent; statistically significant reductions in VLDL electrophoretic levels; (29,7%: P < 0,001) with benfluorex VS., (17,3%; P < 0.001) with the hypolipemic agent; and an increase in HDL electrophoretic levels; benfluorex (10,7%; P < 0,001) VS., (0,9%; P: NS) with the hypolipemic agent.
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D005277:Fenfluramine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D000960:Hypolipidemic Agents; D005277:Fenfluramine; C001584:benfluorex
Etude de l'efficacité du benfluorex et d'un hypolipidémiant de référence en traitement croisé dans les hyperlipidémies de types IV et II b non corrigées par le régime seul.